Godavari Biorefineries Ltd will engage with analysts and institutional investors via a virtual conference on September 29, 2026. The interaction is scheduled as part of the Bharat Connect-Arihant Capital Virtual Conference.

The company informed the stock exchanges that officials will participate in a group meeting format. This disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Meeting Details

The event is structured as a virtual group interaction. No unpublished price-sensitive information will be shared during the session.

Compliance and Disclosure

The company stated that discussions will be based strictly on publicly available information. Manoj Jain, Company Secretary and Compliance Officer, signed the intimation dated September 23, 2026.

Godavari Biorefineries has been granted a patent by the Chinese Patent Office for the use of specific compounds in treating viral infections. The intellectual property right was officially awarded on September 15, 2026.

The company disclosed the development in a regulatory filing dated September 16, 2026, under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notification was addressed to the listing departments of both the National Stock Exchange of India Limited and BSE Limited.

Patent Details

The granted invention relates to the use of compounds for inhibiting V-ATPase activity in cells. This mechanism is further disclosed for its application in the manufacture of medicaments designed to treat viral infections. The patent application was originally filed on May 10, 2021.

The inventors listed on the certificate are M. Atwal, S. Gawade, P. Kakkar, and S. Srivastava. The patent is registered under the name Godavari Biorefineries Limited, with the address listed as Mumbai, India.

What the Numbers Show

The five-year timeline between the initial application in May 2021 and the grant in September 2026 indicates a prolonged examination process typical for complex pharmaceutical patents in international jurisdictions. The successful grant validates the technical novelty of the V-ATPase inhibition approach within the Chinese regulatory framework, securing exclusive rights for the specified therapeutic use.